Navigation Links
Genesis Biopharma Names Marvin S. Hausman M.D. as Chief Science Officer
Date:3/7/2011

LOS ANGELES, March 7, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named Marvin S. Hausman M.D. as Chief Science Officer.  Dr. Hausman has 30 years of drug development and clinical care experience at various pharmaceutical companies.

"We are very fortunate to have Marvin Hausman join the team at Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer. "Dr. Hausman has an outstanding track record in identifying and developing breakthrough medical technologies, and in building companies.  I believe his ability to form successful partnerships and strategic alliances will be an important asset as we grow the Company and create shareholder value."

Dr. Hausman currently serves as Chairman of the Board and Chief Executive Officer of Total Nutraceutical Solutions, Inc.  Previously he was the President, Chief Executive Officer, Acting Principal Accounting and Financial Officer and Chairman of the Board of OXIS International, Inc. until May 2008 when he resigned. Dr. Hausman was also a director and Chairman of the Board of Axonyx from 1997 until the merger of Axonyx into Torrey Pines Therapeutics in October 2006, and had served as President and Chief Executive Officer of Axonyx from 1997 until September 2003 and March 2005, respectively. Dr. Hausman was a co-founder of Medco Research Inc., a pharmaceutical biotechnology company specializing in adenosine products which was subsequently acquired by King Pharmaceuticals. He has also served as a director of Arbios Technologies from 2003 to 2005 and of Regent Assisted Living, Inc. from 1996 to 2001. Dr. Hausman has done residencies in General Surgery at Mt. Sinai Hospital in New York, and in Urological Surgery at UCLA Medical Center. He received his medical degree from New York University School of Medicine in 1967 and is a Board Certified Urological Surgeon.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies.  For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
3. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
4. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
5. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
6. Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
9. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
10. ThermoGenesis Announces National Institute of Health Grant
11. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016  Forge Therapeutics, Inc. today announced a ... EVT, TecDAX, ISIN: DE0005664809) to advance its novel ... of bacterial infections including those caused by drug ... attractive antibacterial target for more than the past ... starting points has hampered its progress. Forge has ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY ... ... reducing loss of blood during surgeries, lowering the risks of ... decreasing risks of SSIs. The patient warming systems can be ... warming systems.These benefits in turn reduce the stay at hospitals ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... will become Quality Insights beginning January 1, 2017. The name change aligns ... commitment to measuring and improving health care quality. , “We are very proud ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... Suite 10.2 version gives development continuity to its innovative Unified Instance Manager ... management capacity. In addition, this new version optimizes the unattended auto-dialing system ...
Breaking Medicine News(10 mins):